Showing 1721-1730 of 4063 results for "".
- Adverum Announces Postive LUNA Phase 2 and OPTIC Long-Term Data on Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-announces-postive-luna-phase-2-and-optic-long-term-data-on-gene-therapy-for-wet-amd/2482546/Adverum Biotechnologies has released 52-week topline results from its phase 2 LUNA trial and new 4-year follow-up data from the OPTIC phase 1/2 study on its wet AMD gene therapy candidate Ixo-vec (AAV.7m8-aflibercept). “We are thrilled to report 52-week LUNA d
- Yuyu Pharma Announces Topline Results from the ICECAP Phase 1/2 Trial of YP-P10 in Dry Eye Diseasehttps://modernod.com/news/yuyu-pharma-announces-topline-results-from-the-icecap-phase-12-trial-of-yp-p10-in-dry-eye-disease/2481651/Yuyu Pharma announced topline results from the ICECAP phase 1/2 trial of YP-P10 in patients with dry eye disease. ICECAP was the first human, signal-seeking, phase 1/2 trial evaluating the safety and efficacy of YP-P10 over 12 weeks (85 days) of treatment in subjects with dry eye disease, ac
- MeiraGTx Announces Topline Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Vision in XLRP Patientshttps://modernod.com/news/meiragtx-announces-positive-topline-data-from-the-mgt009-phase-12-clinical-study-demonstrating-safety-and-improvement-in-vision-in-xlrp-patients/2480936/MeiraGTx Holdings announced topline data from the phase 1/2 clinical study MGT009 (
- Isarna Therapeutics Presents Update From Phase 2 BETTER Study in Wet AMD and DME at the EURETINA Meetinghttps://modernod.com/news/isarna-therapeutics-presents-update-from-phase-2-better-clinical-study-in-wet-amd-and-dme-at-the-euretina-meeting/2481056/Isarna Therapeutics presented an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022. Marion Munk, MD, PhD, FEBO, and the CMO of Isarna Therapeutics provided initial positive safety results and effic
- Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-initial-clinical-data-from-ongoing-phase-12-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481028/Viridian Therapeutics announced positive initial clinical data from the 10mg/kg cohort in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). The double-blind, placebo-controlled phase 1/2 trial is evaluating
- Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 COMET-2 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-phase-3-comet-2-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2480879/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-2” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in t
- Aramis Biosciences Receives FDA Clearance to Proceed with Phase 2 Trail of A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aramis-biosciences-receives-fda-clearance-to-proceed-with-phase-2-trail-of-a197-a-novel-immunomodulatory-agent-for-the-treatment-of-dry-eye-disease/2480558/Aramis Biosciences announced that the FDA has cleared the investigational new drug (IND) application for A197, enabling the company to proceed with a phase 2 proof of concept clinical trial. “We are pleased that FDA has cleared A197 to move into phase 2 clinica
- Ocular Therapeutix Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-topline-results-for-phase-2-clinical-trial-of-otx-ded-for-the-short-term-treatment-of-dry-eye-disease/2480496/Ocular Therapeutix announced positive topline results from its phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The phase 2 clinical trial is a US-based, randomized, double-masked, vehicle-controlled, m
- Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 Phase 2 Clinical Trial in Patients with Macular Edema Due to RVOhttps://modernod.com/news/aerie-pharmaceuticals-reports-positive-topline-results-for-ar-1105-phase-2-clinical-trial-in-patients-with-macular-edema-due-to-rvo/2478079/Aerie Pharmaceuticals reported positive topline results for the company’s phase 2 clinical trial evaluating AR-1105 (dexamethasone intravitreal implant) in patients with macular edema associated with retinal vein occlusion. AR-1105 Phase 2 Highlights
- UK Officials Defend Contingency Plan to Mix COVID-19 Vaccines in Rare Caseshttps://modernod.com/news/uk-officials-defend-contingency-plan-to-mix-covid-19-vaccines-in-rare-cases/2478710/According to a guidance update on December 31, the UK government will allow people to be given doses of different COVID-19 vaccines under certain circumstances, despite a lack of evidence about the extent of immunity offered by such mixing. The issue has sparked criticism after a report in Th